Brendan Jenkins has been selected as the recipient of the ICIS 2023 Distinguished Service Award

Professor Brendan J. Jenkins
Centre Director, Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, Australia (until July, 2023)
Program Head, Tumour Inflammation and Immunotherapy Program, South Australian immunoGENomics Cancer Institute SAiGENCI (beginning in July, 2023), The University of Adelaide, Adelaide, South Australia

Twitter: @Lab_Jenkins

Brendan Jenkins has been selected as the recipient of the ICIS 2023 Distinguished Service Award in recognition of his reputation in the community as both an outstanding cytokine scientist and a remarkably dedicated member of the ICIS. As the lead organizer of the annual meeting in Melbourne in 2014 and his continued service to the Society since 2016 as the Chair of the ICIS Meetings Committee. This is not a simple task and is an area where Brendan has dedicated himself to making this a transparent and fair process. The society benefits tremendously from his participation and service. The Awards Committee has chosen Brendan for this award in appreciation of his long-term commitment to cytokine & interferon research, and his all-important contributions to our society.

After 18 years at the Hudson Institute of Medical Research in Melbourne, Australia, the last 2 years as Centre Head (Centre for Innate Immunity and Infectious Diseases), Professor Brendan Jenkins has accepted a new and exciting position back in Adelaide as Program Lead for the Tumour Inflammation and Immunotherapy Program at the new South Australian ImmunoGENomics Cancer Institute (SAiGENCI). Professor Jenkins specialises in the role of innate immunity in precancerous chronic inflammatory conditions such as gastritis and pancreatitis, and inflammation-associated cancers, in particular gastric (stomach), pancreatic and lung cancers. As part of his role, Professor Jenkins will help build immunology expertise at the University of Adelaide. The knowledge gained by his research has already had a significant impact on biomarker and drug development and in multiple scientific and medical fields, including cancer biology, oncology, immunology, gastroenterology and respiratory medicine. Professor Jenkins will commence as Program Lead at SAiGENCI on 3 July 2023. He is actively recruiting great talent to join his program. https://www.adelaide.edu.au/saigenci/about-saigenci

The Awards Presentation will take place during Cytokines 2023 on Sunday evening, October 15th at the Divani Caravel Hotel in Athens, Greece.

author avatar
joefner@cytokinesociety.org